

Sergio Leonardi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4693963/sergio-leonardi-publications-by-citations.pdf>
Version: 2024-04-03

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130 papers	5,334 citations	30 h-index	71 g-index
143 ext. papers	6,601 ext. citations	7.5 avg, IF	4.84 L-index

#	Paper	IF	Citations
130	Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. <i>Lancet, The</i> , 2015 , 385, 2465-76	40	790
129	Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2012 , 366, 20-33	59.2	570
128	Effect of platelet inhibition with cangrelor during PCI on ischemic events. <i>New England Journal of Medicine</i> , 2013 , 368, 1303-13	59.2	560
127	Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 2975-80	27.4	346
126	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015 , 373, 997-1009	59.2	263
125	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. <i>Lancet, The</i> , 2013 , 382, 1981-92	40	234
124	Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 1055-63	5	163
123	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2018 , 392, 835-848	40	129
122	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019 , 7, 618-628	18.1	120
121	Digoxin and Mortality in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1063-1074	15.1	99
120	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 387-396	15.1	96
119	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2592-2592	15.1	95
118	Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study. <i>JAMA Cardiology</i> , 2020 , 5, 1274-1280	16.2	95
117	Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2009 , 30, 2003-10	9.5	72
116	Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 441-52	4.3	66
115	A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. <i>Circulation: Cardiovascular Interventions</i> , 2013 , 5, 220-41	6	66
114	Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). <i>American Heart Journal</i> , 2013 , 166, 65-72	4.9	65

113	Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial. <i>American Heart Journal</i> , 2012 , 163, 768-776.e2	4.9	64
112	Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. <i>European Heart Journal</i> , 2015 , 36, 1242-51	9.5	61
111	Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. <i>European Journal of Heart Failure</i> , 2020 , 22, 2238-2247	12.3	58
110	A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 417-434	5	52
109	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2223-2234	15.1	51
108	Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2021 , 385, 1643-1655	59.2	46
107	Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. <i>European Heart Journal</i> , 2014 , 35, 2524-9	9.5	39
106	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. <i>American Heart Journal</i> , 2019 , 209, 97-105	4.9	39
105	Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study trial. <i>American Heart Journal</i> , 2016 , 174, 95-102	4.9	37
104	Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. <i>BMJ, The</i> , 2016 , 354, i4935	5.9	36
103	Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRAICER) trial. <i>European Heart Journal</i> , 2013 , 34, 1723-31	9.5	34
102	COVID-19 and Disruptive Modifications to Cardiac Critical Care Delivery: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 72-84	15.1	32
101	Myocarditis in a 16-year-old boy positive for SARS-CoV-2. <i>Lancet, The</i> , 2020 , 395, e116	4.0	31
100	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 36-50	5	30
99	Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 242-251	15.1	29
98	Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1576-1586	5	28
97	Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1231-1242	15.1	27
96	A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. <i>Heart</i> , 2013 , 99, 1282-7	5.1	27

95	Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. <i>EuroIntervention</i> , 2016 , 11, e1222-30	3.1	27
94	Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	23
93	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018 , 138, 1666-1676	16.7	23
92	Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015 , 86, E19-27	2.7	23
91	Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2296-304	15.1	23
90	Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. <i>Drugs</i> , 2010 , 70, 1771-83	12.1	23
89	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). <i>Circulation</i> , 2016 , 134, 723-33	16.7	23
88	Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. <i>International Journal of Cardiology</i> , 2016 , 212, 112-117	3.2	22
87	Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial. <i>European Heart Journal</i> , 2019 , 40, 1226-1232	9.5	21
86	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. <i>European Heart Journal</i> , 2016 , 37, 1122-30	9.5	20
85	Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. <i>European Heart Journal</i> , 2013 , 34, 894-902d	9.5	20
84	Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 168-78	6.4	19
83	Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 375-388	15.1	19
82	Remote ischemic postconditioning as a strategy to reduce acute kidney injury during primary PCI: a post-hoc analysis of a randomized trial. <i>International Journal of Cardiology</i> , 2014 , 177, 500-2	3.2	17
81	Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 61-70	3.9	16
80	Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2015 , 115, 1325-32	3	16
79	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 856-864	5	16
78	Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 665-73	3	16

77	Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014 , 113, 936-44	3	16
76	Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA). <i>European Heart Journal</i> , 2014 , 35, 199-207	6.4	16
75	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). <i>BMJ Open</i> , 2019 , 9, e026053	3	15
74	Drug eluting stents are superior to bare metal stents to reduce clinical outcome and stent-related complications in CKD patients, a systematic review, meta-analysis and network meta-analysis. <i>Journal of Interventional Cardiology</i> , 2018 , 31, 319-329	1.8	15
73	2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTEMI-ACS guideline group. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 224-233	4.3	15
72	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1289-97	15.1	13
71	Promises of PAR-1 inhibition in acute coronary syndrome. <i>Current Cardiology Reports</i> , 2012 , 14, 32-9	4.2	13
70	Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002314	6	13
69	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	13
68	Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. <i>EuroIntervention</i> , 2018 , 13, e1841-e1849	3.1	12
67	Practical considerations for cangrelor use in patients with acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 39-44	4.3	12
66	Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 758-774	15.1	11
65	Appropriateness of percutaneous Coronary interventions in patients with ischaemic HEart disease in Italy: the APACHE pilot study. <i>BMJ Open</i> , 2017 , 7, e016909	3	11
64	Patients with acute coronary syndrome and nonobstructive coronary artery disease in the real world are markedly undertreated. <i>Journal of Cardiovascular Medicine</i> , 2011 , 12, 700-8	1.9	11
63	Optimised care of elderly patients with acute coronary syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 287-295	4.3	10
62	Elevated serum uric acid affects myocardial reperfusion and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19, 240-246	1.9	10
61	Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX). <i>Current Cardiology Reports</i> , 2014 , 16, 493	4.2	10
60	PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. <i>Handbook of Experimental Pharmacology</i> , 2012 , 239-60	3.2	10

59	Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 361-373	5	10
58	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021 , 44, 1219-1227	14.6	9
57	Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. <i>American Heart Journal</i> , 2016 , 178, 1-8	4.9	9
56	Comparison of Outcomes of Staged Complete Revascularization Versus Culprit Lesion-Only Revascularization for ST-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2017 , 119, 508-514	3	8
55	Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2018 , 196, 28-35	4.9	8
54	Rationale and design of the Hunting for the off-target properties of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. <i>American Heart Journal</i> , 2017 , 189, 128-136	4.9	7
53	Early Complete Revascularization in Hemodynamically Stable Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 1047-1057	3.8	7
52	Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1289-1291	15.1	7
51	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. <i>International Journal of Cardiology</i> , 2018 , 270, 96-101	3.2	7
50	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 158-165	4.3	6
49	Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. <i>EuroIntervention</i> , 2020 , 16, 627-633	3.1	6
48	Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e006581	5.8	6
47	Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2018 , 273, 80-87	3.2	5
46	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007342	6	5
45	Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EMPLOYED antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units Registry. <i>Journal of Cardiovascular Medicine</i> , 2017 , 18, 580-589	1.9	5
44	Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease. <i>Therapeutics and Clinical Risk Management</i> , 2014 , 10, 321-9	2.9	5
43	Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2012 , 164, 502-8	4.9	5
42	Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. <i>EuroIntervention</i> , 2021 ,	3.1	5

41	Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 570-576	1.9	5
40	Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. <i>International Journal of Cardiology</i> , 2015 , 190, 242-5	3.2	4
39	Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 893-901	0.7	4
38	Clinical governance programme in patients with acute coronary syndrome: design and methodology of a quality improvement initiative. <i>Open Heart</i> , 2020 , 7,	3	4
37	A Blind Study of Four Digital Rock Physics Vendor Laboratories on Porosity, Absolute Permeability, and Primary Drainage Capillary Pressure Data on Tight Outcrops. <i>Petrophysics</i> , 2018 , 59, 15-24	2	4
36	Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study. <i>Europace</i> , 2021 , 23, 1603-1611	3.9	4
35	Prasugrel and ticagrelor compared to clopidogrel in non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary interventions: Certainties and uncertainties. <i>International Journal of Cardiology</i> , 2015 , 181, 443-5	3.2	3
34	Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome. <i>Advances in Cardiology</i> , 2012 , 47, 87-99		3
33	Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study).. <i>American Journal of Cardiology</i> , 2022 ,	3	3
32	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 444-456	5	3
31	Is the use of risk scores an indicator of guideline adherence for patients with acute coronary syndromes? Insights from the EYESHOT Registry. <i>International Journal of Cardiology</i> , 2015 , 187, 80-3	3.2	2
30	Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19, 373-381	1.9	2
29	Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. <i>Coronary Artery Disease</i> , 2013 , 24, 321-7	1.4	2
28	Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , 2020 , 220, 82-88	4.9	2
27	Lugar de acceso y tipo de anticoagulante en pacientes con síndrome coronario agudo en clase Killip avanzada o con parada cardíaca extrahospitalaria. <i>Revista Espanola De Cardiologia</i> , 2020 , 73, 893-901	1.5	2
26	Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 987-993	3.9	2
25	: An updated meta-analysis on aspirin use in primary prevention of cardiovascular disease in patients with diabetes. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 1677-1679	3.9	2
24	Lack of implementation of guidelines recommendations for coronary revascularization in stable patients with complex disease is associated with high rates of incomplete revascularization : Analysis from the Apache study. <i>Heart and Vessels</i> , 2020 , 35, 30-37	2.1	2

23	Early intra-aortic balloon pump in acute decompensated heart failure complicated by cardiogenic shock: Rationale and design of the randomized Altshock-2 trial. <i>American Heart Journal</i> , 2021 , 233, 39-47	4.9	2
22	Meta-Analysis Comparing Potent Oral P2Y Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 21, 231-240	4	2
21	Cangrelor use in a 6-year-old patient undergoing complex percutaneous coronary intervention after post-surgical myocardial infarction. <i>Platelets</i> , 2020 , 31, 1090-1093	3.6	1
20	Barriers associated with emergency medical service activation in patients with ST-segment elevation acute coronary syndromes. <i>Internal and Emergency Medicine</i> , 2021 , 1	3.7	1
19	Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes. <i>Minerva Endocrinology</i> , 2017 , 42, 228-237	2.5	1
18	Percutaneous coronary interventions for stable ischemic heart disease in Italy. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 762-767	1.9	1
17	The prognostic value of late gadolinium enhancement in hypertrophic cardiomyopathy: An updated meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1902-1905	3.9	1
16	DAPT Score to Stratify Ischemic and Bleeding Risk after Percutaneous Coronary Intervention: An Updated Systematic Review, Meta-Analysis, and Meta-Regression of 100,211 Patients. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 687-689	7	1
15	Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2021 , 59, 522-531	3	1
14	Incidence of Ventricular Arrhythmias and 1-Year Predictors of Mortality in Patients Treated With Implantable Cardioverter-Defibrillator Undergoing Generator Replacement. <i>Journal of the American Heart Association</i> , 2021 , 10, e018090	6	1
13	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.. <i>Circulation: Cardiovascular Interventions</i> , 2021 , CIRCINTERVENTIONS120010390	6	0
12	Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 83-93	4.3	0
11	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 ,	4.3	0
10	Acute Cardiovascular Care 2019. <i>European Heart Journal</i> , 2019 , 40, 1903-1906	9.5	
9	The Fall and Rise of Cangrelor. <i>Drug Development Research</i> , 2013 , 74, 526-532	5.1	
8	Parenteral antithrombotic therapy during primary percutaneous coronary intervention. <i>Minerva Cardiology and Angiology</i> , 2018 , 66, 411-421	2.4	
7	Will PIONEER AF-PCI change my practice?. <i>EuroIntervention</i> , 2017 , 13, e609-e612	3.1	
6	Around the clock, around the world-reflections on 24 hours of acute cardiovascular care. <i>European Heart Journal</i> , 2021 , 42, 4707-4709	9.5	

- 5 Acute myocardial infarction complicating ischemic stroke: is there room for cangrelor?. *Platelets*, **2020**, 31, 120-123 3.6
- 4 Reply: Digoxin Use in Atrial Fibrillation: Minimizing and Refining its Use When Still Needed. *Journal of the American College of Cardiology*, **2018**, 72, 125-126 15.1
- 3 Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention [Insights from the CHAMPION program. *American Heart Journal Plus*, **2021**, 9, 100043
- 2 Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.. *Circulation: Cardiovascular Interventions*, **2022**, CIRCINTERVENTIONS121011069 6.9
- 1 ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes. *European Heart Journal Supplements*, **2022**, 24, C254-C271 1.5